LYEL
Lyell Immunopharma, Inc. · Healthcare · Market cap $269.8M
Insiders sold $227K net in the last 90 days ·6 sellers, 0 buyers· latest Form 4 filed Sep 10, 2026
Insider Buying
$25.0M
reported purchases (SEC code P)
Insider Selling
$605K
reported sales (SEC code S)
Unique Insiders
8
in the rolling window
Latest filing
Sep 10, 2026
Shook David
Lyell Immunopharma, Inc. (LYEL) has 33 SEC Form 4 filings (38 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: Sep 10, 2026.
Inside the rolling window, 8 insiders at Lyell Immunopharma, Inc. reported 2 open-market purchases totaling $25.0M and 28 open-market sales totaling $605K. The most active filer is Chief Scientific Officer Lee Gary K. with 6 filings. Insiders have net sold $252K over the trailing 6 months. The most recent open-market filing is a sale of 500 shares by Chief Medical Officer Shook David, dated Sep 10, 2026, worth $6K.
- Industry:Biotechnology
- CEO:Lynn Seely
- Employees:161
- HQ:South San Francisco, CA, US
- IPO:2021-06-17
| Source | |||||||
|---|---|---|---|---|---|---|---|
Shook DavidFirst in 3 months | Chief Medical Officer | Sale | 500 | $6K | Sep 10 | -9.8% | SEC ↗ |
| Chief Scientific Officer | Sale | 1,457 | $23K | Aug 25 | -28.9% | SEC ↗ | |
| Chief Operating Officer | Sale | 989 | $15K | Aug 25 | -28.9% | SEC ↗ | |
| President and CEO | Sale | 9,589 | $149K | Aug 25 | -28.9% | SEC ↗ | |
| Chief Scientific Officer | Sale | 131 | $2K | Aug 11 | -22.3% | SEC ↗ | |
| President and CEO | Sale | 390 | $6K | Aug 11 | -22.3% | SEC ↗ | |
| VP, Corporate Controller | Sale | 621 | $9K | Aug 11 | -22.3% | SEC ↗ | |
| Chief Operating Officer | Sale | 89 | $1K | Aug 11 | -22.3% | SEC ↗ | |
| 10% Owner | Sale | 10 | $137 | Jul 20 | -14.8% | SEC ↗ | |
Innovative Cellular Therapeutics Holdings LtdFirst filing | 10% Owner | Sale | 10 | $137 | Jul 18 | -14.8% | SEC ↗ |
Seely LynnFirst in 4 months | President and CEO | Sale | 388 | $7K | Jun 15 | — | SEC ↗ |
Lee Gary K.First in 4 months | Chief Scientific Officer | Sale | 130 | $2K | Jun 15 | — | SEC ↗ |
Hill Stephen J.First in 4 months | Chief Operating Officer | Sale | 89 | $2K | Jun 15 | — | SEC ↗ |
Bulis Veronica SanchezFirst in 4 months | VP, Corporate Controller | Sale | 217 | $4K | Jun 15 | — | SEC ↗ |
Shook DavidFirst filing | Chief Medical Officer | Sale | 1,977 | $25K | Jun 11 | — | SEC ↗ |
ARCH Venture Partners IX, LLCFirst filing | 10% Owner | Purchase | 488,090 | $12.5M | Mar 9 | — | SEC ↗ |
ARCH Venture Fund XIII, L.P.First filing | 10% Owner | Purchase | 488,090 | $12.5M | Mar 9 | — | SEC ↗ |
| Chief Operating Officer | Sale | 1,236 | $29K | Feb 12 | — | SEC ↗ | |
| Chief Scientific Officer | Sale | 1,671 | $39K | Feb 12 | — | SEC ↗ | |
| President and CEO | Sale | 7,455 | $174K | Feb 12 | — | SEC ↗ | |
Hill Stephen J.First in 3 months | Chief Operating Officer | Sale | 109 | $3K | Feb 11 | — | SEC ↗ |
Seely LynnFirst in 3 months | President and CEO | Sale | 438 | $10K | Feb 11 | — | SEC ↗ |
Lee Gary K.First in 3 months | Chief Scientific Officer | Sale | 147 | $3K | Feb 11 | — | SEC ↗ |
| VP, Corporate Controller | Sale | 254 | $6K | Feb 11 | — | SEC ↗ | |
| VP, Corporate Controller | Sale | 1,136 | $44K | Jan 6 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does LYEL have?
Lyell Immunopharma, Inc. (LYEL) has 33 SEC Form 4 filings (38 transaction rows) in the rolling 365-day window, disclosed by 8 distinct insiders. Most recent filing: Sep 10, 2026.
When was the most recent SEC Form 4 filing for LYEL?
The most recent Form 4 filing for LYEL on Tracefour is dated Sep 10, 2026.
Who is the most active insider at LYEL?
The most active SEC Form 4 filer at LYEL in the rolling window is Chief Scientific Officer Lee Gary K., with 6 filings.
What is the net insider flow at LYEL over the last 6 months?
Over the trailing 180 days, insiders at LYEL have net sold $252K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at LYEL in the current window?
Inside the rolling window, insiders at LYEL bought $25.0M and sold $605K based on SEC Form 4 filings.
Can I get alerts for LYEL insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Lyell Immunopharma, Inc. (LYEL). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Lyell Immunopharma, Inc. is in the Healthcare sector.